Posts Tagged ‘successfully’
PositiveID Corporation Successfully Completes Phase I Development Of Its Rapid Virus Detection System
PositiveID Corporation (“PositiveID” or the “Company”) (NASDAQ:PSID), in conjunction with its development partner RECEPTORS LLC (“Receptors”), announced today that it has successfully completed Phase I development of its rapid virus detection system, a non-invasive, point-of-care test to test patient samples and identify various forms of influenza within minutes…
Radiation Therapy Technique Successfully Treats Pain In Patients With Advanced Cancer
Stereotactic radiosurgery (SRS), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, effectively controls pain in patients with cancer that has spread to the spine, according to researchers from UPCI. The results of the research were presented this week during the American Society for Radiation Oncology (ASTRO) annual meeting in Chicago, being held November 1 – 5, 2009.
Mesoblast Limited (ASX:MSB) Proprietary Stem Cells Successfully Repair/Regenerate Damaged Intervertebral Disc Cartilage
Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced highly successful preclinical trial results of its adult stem cells in the treatment of degenerative intervertebral disc disease, the leading cause of low back pain.
PAION Announces Patient Recruitment For Phase IIa Study With Its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract. “Again our development team has beaten our expectations. We will be able to provide headline data by November,” commented Dr.
Funxional Successfully Completes Initial Clinical Trial Of FX125L, An Anti-Inflammatory Drug With A Novel Mechanism Of Action
Funxional Therapeutics Ltd (Funxional) has announced the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed.
Three Surgeons In East Texas Are Successfully Integrating A Novel Stem Cell Procedure For Spine Surgeries
A new breakthrough in adult stem cell technology has three Texarkana neurosurgeons leading their industry by utilizing concentrated stem cells for spine surgery. The innovative technique is improving the desired results of surgical interventions for back pain. Leading researchers in the orthopedic and spine industry are predicting the latest developments in this field of medicine will become mainstream practice and, potentially, a standard of care for surgical treatments of severe back pain.
QRxPharma Successfully Completes Comparative Study For Dual-Opioid(TM) Pain Therapy
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced the successful completion of a Phase 3 program pilot study comparing the efficacy and safety profile of MoxDuo(TM) IR against component doses of morphine and oxycodone. Results demonstrated that MoxDuo(TM) IR reduces pain significantly more than its component doses; further, when compared to equianalgesic doses of morphine and oxycodone, MoxDuo(TM) IR produced fewer and less intense side effects.
Rx Drug Compare
Translator
By N2H